From treatments for cancer to breakthroughs in stem cells and the printing of organs in 3D, scientists are creating new trends that we believed could only be described as science fiction (although we’re still not able to have the capability of teleportation). Imagine what a smaller footprint of the environment could be if we had the capability of teleportation. Scientists Do your job.
Return to the real world and tangible.
Many of the biggest advancements in medical research have come from research conducted in the field of biotech.
What exactly is biotech? And why is it attracting billions of dollars of investment?
In this article we’ll attempt to address these questions and many more. We’ll discuss the biotech industry, its significant technological breakthroughs and the reasons it is attracting huge sums of money, and the reasons to consider biotech stocks as part of your portfolio of investments.
Biotech is what?
You’ve heard of the phrase. It’s got something to do with the latest breakthroughs in medical research. But, it’s more than that.
There are five areas of biotechnology that can be classified into:
Human
Environmental
Industrial
Animal
Plant
Each of these branches aids to combat hunger and illness. They aid in sustainable production, and could aid in reducing our environmental footprint and help save energy.
Biotechnological processes also play a role in the wine and beer you consume and the bread you consume and the milk that is lactose-free.
Bread and beer in the background, biotech usually linked to researchers and doctors looking to develop and hopefully creating medicines derived from living organisms with the help of technology.
In simple terms, it’s the combination of biology and technology.
In the field of medicine, biotech could be utilized to treat rare and debilitating illnesses and enhance the quality of life. This has included the creation of vaccines that combat everything from measles, hepatitis Mumps, measles and even some of the most prevalent cancers like cervical vaccines, such as Merck’s Gardasil(r).
The most significant innovations made in biotech include.
Stem cell research
Nerve regeneration
Cancer therapies that target specific areas
Gene editing
Human genomic sequencing
Augmented real-time in surgery
Organs 3D printed
Plus…
Biotech is a major topic
With the many breakthroughs that have been made in biotech, it’s not surprising that this field attracts billion-dollar deals as well as large investment.
A successful biotech business can see huge growth in both profits and revenue.
Grandview Research reports the global biotechnology market is predicted to grow to $2.44 trillion by 2028.
This could be aided through this COVID-19 pandemic.
Pfizer reported revenue of 86% increase in its second quarter 2021. the sale of COVID-19 vaccine was not included in the figures.
The results of Pfizer’s third quarter showed revenues of $24.1 billion, as compared with the forecast for $23.5 billion, and a $22.6 billion as the consensus estimate.
The bottom line for the company of $1.34 per share basis and an adjusted basis was up 133% over the previous year.
Whatever you think about COVID-19, vaccines generally are a major growth engine for any business. For Pfizer the quarter ended, it made revenues of $13 billion in the period.
Nine-month revenue (ending in September of 2021) for the vaccine is at over $24 billion. The forecast is of $36 billion for whole year 2021 and $30 billion by 2022.
Pfizer is among the largest corporations worldwide and is an example of the amount of money that biotech companies can earn when it is able to nail its products. If you’re a small-sized company and big pharma is a possibility, they could call you to buy you.
The $2 billion investment by Blackstone of $2 billion in Alnylam Pharmaceuticals (NASDAQ:ALNY) in April 2020 was one the largest private financings of biotech companies.
The numbers are good for these companies as well as their investors.
It is also worth noting AstraZeneca’s deal worth $39 billion for Alexion Pharmaceutical and Gilead’s $21 billion purchase of Immunomedics.
In 2020 Top 10 transactions witnessed around $97 billion worth of biopharma assets swapped. This was less than the almost $207 billion reported in the year prior, but this is because of the pandemic, and the fact that the wheel is now getting ready to spin.
The most important biotech drug
Statista states the fact that AbbieVie and Roche hold the most biotech-related drugs available. Roche is the largest biotech firm globally, with its prescription drug biotech revenue expected to be over $US48 billion by 2028.
Roche’s Avastin drug was responsible for about $US7.1 billion in 2019 , before the pandemic struck. Avastin helps to block the growth of blood vessels in order to treat certain kinds of cancer. Roche’s Rituxan is used to treat immune-mediated diseases and forms of cancer. It generated $4.5 billion last year.
The AbbiVie’s Humira is an antirheumatic medicine. The drug treats severe to moderate rheumatoid joint in adults. It is expected to generate $US19.8 billion by 2020.
What is an “blockbuster?
It’s not a duplicate video store and neither is it an Marvel film, or anything featuring Tom Cruise.
A biotech blockbuster is a medicine that earns more than 1 billion dollars in revenue.
The drugs consist of Lipitor as well as Zoloft and are used to are used to treat common medical conditions such as high cholesterol high blood pressure, diabetes as well as cancer, asthma and diabetes.
Every biotech is eager to develop blockbuster drugs , and every investor is encouraging biotech companies to develop blockbuster drugs.
A blockbuster drug could be the catalyst for biotech companies, but for investors there aren’t any big dollar signals. There are risks when investing in biotechnology, and you must be on watch when you are deciding on which stocks you should invest your money in.
The benefits for investing in biotech
The importance of diligence is crucial to the success of your biotech investment.
A rigorous level of examination is needed to separate what is wheat and what’s chaff.
A biotech stock , one that represents a business in the biotech industry – is often the most difficult stock to select effectively.
Biotech investments carry huge risks. While making investments in biotech firms could yield huge profits There exist pros as well as cons that every investor must be aware of.
Let’s start with the pros.
Products that are required
Biotech companies have the ambition to develop new technologies and medicines that could transform the world: stop the spread of diseases and end hunger in the world …
Anything that claims to accomplish this and is backed by the appropriate finance, personnel and even a product idea is an organization to be watching.
The products must satisfy a community’s need, and if they don’t then don’t bother.
A growing market
Although the figures vary from research houses biotech is an expanding market. Global Market Insights predicts the market will increase to $950 billion by 2027.
This is due to the rise in chronic diseases and associated health costs.
A business that helps reduce pain or illness through the production of drugs will flourish. Additionally an organization that has cutting-edge technology products can reduce costs and lessen health care burden.
These companies can grow by leaps and bounds in their value.
Fior Markets predicts the biotech sector to experience an annual compound increase of 7.02 percent between 2020-2027 and will reach US$833.34 billion by the end forecast time.
Grandview Research estimates the global biotechnology market will grow to $2.44 trillion.
ESG
Biotech companies provide investors with the opportunity to invest in socially responsible companies.
They generally address the needs of investors regarding environmental ethics, corporate governance, and environmental aspects, in addition to financial returns.
Investors who are ethical invest based on their personal values, and the majority of biotech companies are working to create a better society and also for the planet.
Portfolio with a balanced balance
Biotech stocks are a way to maintain an appropriate portfolio.
In addition to allowing investors to invest in cutting-edge technology, they also can increase their portfolios with a an array of high-risk, lucrative investments such as promising biotech small caps such as Imugene Ltd (ASX:IMU, OTC: IUGNF), Noxopharm Ltd (ASX:NOX) (brain cancer), Chimeric Therapeutics Ltd (ASX:CHM) (cell therapy), Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) (bone Marrow and treatments for liver cancer), Arovella Therapeutics Ltd (iNKT cell therapy platform) as well as Kazia Therapeutics Ltd (ASX:KZA, KZIA, NASDAQ:KZIA) (newly identified glioblastoma) in addition to more well-established, profitable companies like Roche.
Earn money
A stake in biotech stocks can yield a profit. If you’re at the first position following the launch of a successful product the latest treatment, it is normal to see shares increase.
If it’s an equities company The sky is the limit.
If it’s Pfizer during a pandemic there’s an opportunity to gain realized.
But, caution is needed. There are many companies that will not achieve a breakthrough or create an action-packed blockbuster. As we’ve stated that due diligence is essential and professional advice is recommended prior to making a decision for a biotech stock.
The pros and cons to investing your money in biotechnology
Commercial failures
Biotech companies may create what appears to be the most effective product on the market however that doesn’t mean it’s going to be an overnight commercial success.
It costs thousands of dollars develop products and, when it fails to earn its profit, you’re likely to see your reduction in the price of shares.
Clinical failures
Before even reaching the stage of commercialization the product must go through a series of tests.
Many times, those tests are unsuccessful and then it’s again back to the drawing board with millions of dollars being wasted.
When you’re considering a biotech stock take note of the they are currently at.
The first stage is the discovery and research stage and is the most risky. There isn’t a product.
Preclinical Stage II is, and is also extremely risky. The need for capital is a requirement and regulatory hurdles need to be overcome.
Stage 3 is the stage where companies at the clinical stage have developed their product and have it accepted for human clinical trials. This stage can bring short-term benefits, but it is also rife with risks.
Anything that is later in the process is less risky. Biotech companies that are in late clinical stage, the end of their journey to bring new medical products on the market , and commercial stage companies are ones to keep an eye on.
The money is not there.
Some biotech companies in the early stages are unable to find the funds they need to conduct trials. Beware of companies that are who are struggling to find capital.
Consider the risk vs. reward prior to making a decision to invest
There are many great benefits as well as great risks associated with investing in biotech.
Do your homework.
The more well-prepared you are, and the more information you know the better decision you’ll be able to make.
In simple terms, be cautious and be aware of your risk tolerance.